Charles Brown, MD
Cardiovascular Disease · Atlanta, GANPI 1851307755
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $34,145 of the $40,699 with a category attached, or 83.9%. Boston Scientific accounts for 84.8% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $34,971 and has fallen 97.7% since, to $806 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $216.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$35K
- Medtronic$2K
- Novartis$986
- Johnson & Johnson$564
- Cvrx, Inc.$406
- Siemens Medical Solutions USA, Inc.$284
- plus $2K from 21 others
Across 4 payments — averaging $23,465 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$94K
What the payments were for
- Food & beverage$6,55516%
- Ownership interest$34,14584%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $34,504 |
| Medtronic(2 entities) | 18 | $1,714 |
| Novartis | 52 | $986 |
| Johnson & Johnson | 31 | $564 |
| Cvrx, Inc. | 4 | $406 |
| Siemens Medical Solutions USA, Inc. | 2 | $284 |
| Biotronik Inc. | 2 | $260 |
| Abiomed | 2 | $256 |
| Amgen | 13 | $251 |
| AstraZeneca | 9 | $207 |
| Shockwave Medical, Inc | 1 | $192 |
| Pfizer | 9 | $190 |
| Endologix LLC | 1 | $154 |
| E.r. Squibb & Sons, L.L.C. | 8 | $148 |
| Merck | 7 | $122 |
| Acist Medical Systems, Inc. | 1 | $81 |
| Boehringer Ingelheim | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $56 |
| Heartflow, Inc. | 2 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Angiodynamics, Inc. | 1 | $37 |
| Kestra Medical Technology Services, Inc. | 2 | $36 |
| Bayer | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$34,145
- CoreValve Evolut$372
- Barostim Neo System$344
- Orsiro Mission$260
- Visia AF$260
- Impella$256
- RESOLUTE ONYX$208
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$192
- Micra$158
- Torus Stent Graft System$154
- ENDOCROSS Device$154
- CorPath Imaging System$139
- PK Papyrus$135
- COREVALVE EVOLUT R$119
- ENTRESTO$106
How this compares
$40,699 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 138 | $163,517 |
| XareltoRivaroxaban | 73 | $82,805 |
| Rosuvastatin Calcium | 376 | $4,934 |
| Ezetimibe | 142 | $3,209 |
| Ranolazine ErRanolazine | 18 | $2,425 |
| Atorvastatin Calcium | 252 | $2,227 |
| Metoprolol Succinate | 134 | $2,154 |
| Losartan Potassium | 156 | $1,793 |
| Niacin ErNiacin | 13 | $1,346 |
| ClopidogrelClopidogrel Bisulfate | 66 | $1,050 |
| Lisinopril | 120 | $833 |
| Nebivolol Hcl | 14 | $819 |
| Metoprolol Tartrate | 103 | $799 |
| Carvedilol | 73 | $770 |
| Nitroglycerin | 23 | $600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $190 | $163,517138 claims |
| Johnson & JohnsonXarelto | $564 | $82,80573 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Atlanta
- Joseph MillerAtlanta$573K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Mani VannanAtlanta$157K
- Victor CorriganAtlanta$114K
- Elizabeth OfiliAtlanta$107K
- Isida BykuAtlanta$78K
- Cindy GrinesAtlanta$75K
- Anekwe OnwuanyiAtlanta$56K
- Melvin EcholsAtlanta$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.